A key expert panel at the US Food and Drug Administration has unanimously recommended approving Moderna’s new flu vaccine, a decision that could mark the first time mRNA technology is used to fight seasonal influenza. The vote, based on trial data showing a clear advantage over traditional shots, brings the world closer to a faster, more adaptable approach to flu prevention.
The FDA’s Vaccines and Related Biological Products Advisory Committee voted in favor of the vaccine, known as mFlusiva, for adults aged 50 and older. In a late-stage trial, the mRNA shot was found to be about 27 percent more effective than a standard flu vaccine at preventing illness. That difference is significant in a field where effectiveness often fluctuates from year to year depending on how well the vaccine matches circulating virus strains. The committee recommended approval for two age groups: people 50 to 64 and those 65 and older. For the older group, which faces higher risks of severe complications, the panel asked Moderna to conduct an additional study after the vaccine reaches the market.
Traditional flu vaccines are produced using methods that require months of advance planning, forcing manufacturers to choose which strains to target before the winter season begins. By the time the virus arrives, the match can weaken. mRNA technology bypasses that limitation by using a short piece of genetic code that instructs cells to produce a flu-like protein, training the immune system without using live virus. Moderna told the committee it can move from selecting strains to distributing the vaccine in two to three months, compared with about six months for older methods. That speed could allow the vaccine to be updated later in the year, closer to flu season, to better match the strains actually spreading in the community.
Side effects were similar to those seen with other vaccines, including injection site pain, fatigue, muscle aches, and fever. No unusual safety concerns were identified that outweighed the benefits. The call for extra monitoring in the 65-plus group reflects regulatory caution, given the higher risk of severe flu in that population and the complexity of comparing vaccines in older adults.
If the FDA grants final approval, mFlusiva would become the first mRNA-based flu vaccine authorized anywhere in the world. The decision could also accelerate development of combination shots that target both flu and COVID-19 in a single injection, an area where Moderna and other companies are already working. For patients and health systems, the arrival of a more effective, rapidly updatable flu vaccine offers a hopeful step toward fewer hospitalizations and better protection each season.